Search
gadobenate dimeglumine (Multihance)
Tradename: Multihance (FDA-approved in 2004)
Indications:
- used in magnetic resonance imaging (MRI) of the central nervous system (CNS)
Adverse effects:
- may be less likely to cause nephrogenic systemic fibrosis than other gadolinium-based MRI contrast agents [2]
Mechanism of action:
- paramagnetic agent
Notes: Manufacturer: Bracco
General
gadolinium contrast (Omniscan)
Database Correlations
PUBCHEM cid=197281
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- Martin DR et al.
No incidence of nephrogenic systemic fibrosis after gadobenate
dimeglumine administration in patients undergoing dialysis or
those with severe chronic kidney disease.
Radiology 2018 Jan; 286:113
PMID: 28731375
http://pubs.rsna.org/doi/10.1148/radiol.2017170102